PrakashBhuyanMDPhD

Infectious Disease • Philadelphia, PA

Senior Vice President, Clinical Development

Join to view full profile

Dr. Bhuyan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Bhuyan's full profile

Already have an account?

Office
3900 Woodland Ave
University And Woodland Avenues
Philadelphia, PA 19104
Is this information wrong?

Education & Training

University of Pennsylvania Health SystemFellowship, Infectious Disease, 2001 - 2003
Emory University School of MedicineResidency, Internal Medicine, 1998 - 2001
University of Texas Southwestern Medical SchoolClass of 1998

Certifications & Licensure

PA State Medical License 2001 - 2024
GA State Medical License 1999 - 2001

Clinical Trials

Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) Start of enrollment: 2006 May 01
Completed
Phase 2
Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED) Start of enrollment: 2006 Sep 01
Completed
Phase 3
A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057) Start of enrollment: 2006 Oct 06
Completed
Phase 3
Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED) Start of enrollment: 2006 Nov 01
Completed
Phase 3
A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002) Start of enrollment: 2001 May 01
Completed
Phase 2
A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003) Start of enrollment: 2001 May 01
Completed
Phase 2
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) Start of enrollment: 2017 Aug 31
Completed
Phase 2
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) Start of enrollment: 2017 Jun 28
Completed
Phase 3
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 Start of enrollment: 2018 May 15
Completed
Phase 2
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions Start of enrollment: 2018 Sep 21
Active, not recruiting
Phase 2
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) Start of enrollment: 2019 Apr 09
Completed
Phase 3
Hepatitis B Vaccine in Seniors Start of enrollment: 2000 Mar 29
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 M...
Moullan, N., Asiago, J., Hadi, S., Albizem, M., Tieu, H., Hock, B., Fenwick, C., Lin, K., Lengsfeld, T., Poffenbarger, L., Liu, D., Trono, D., Pantaleo, G., Stecco, K....> ;Infectious Diseases and Therapy. 2024 Jan 1
40 citations
Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis.
Prakash Bhuyan, Jennie Medin, Hugo Gomes da Silva, Madhavi Yadavalli, Nirmal Kumar Shankar, Hana Müllerová, M. Arnold, Magnus Nord> ;Lancet. 2021 Aug 14
16 citations
Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL.
Prakash K. Bhuyan, Michael J. Dallas, Kim Kraynyak, Timothy A. Herring, Matthew P. Morrow, Jean D. Boyer, Susan Duff, Joseph L. Kim, David B. Weiner> ;Human Vaccines & Immunotherapeutics. 2021 May 4
3 citations
Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population
Rebecca K. Hollenberg, Diane Krieger, Robert Samuels, Kim Kraynyak, Albert Sylvester, Matthew P. Morrow, Jean D. Boyer, Michael J. Dallas, Prakash K. Bhuyan> ;Human Vaccines & Immunotherapeutics. 2020 Jun 2
10 citations
Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers.
David M. Reiner, Prakash Bhuyan, Joseph Eiden, John Ginis, Shannon L. Harris, Kathrin U. Jansen, Qin Jiang, Thomas R. Jones, Robert E. O’Neill, Laura J. York, John L. ...> ;Vaccine. 2016 Feb 3
Repurposing historical control clinical trial data to provide safety context.
Prakash Bhuyan, Jigar Desai, Matthew St Louis, Martin Carlsson, Edward A Bowen, Mark M Danielson, Michael N. Cantor> ;Drug Discovery Today. 2016 Feb 1
9 citations
Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
Christopher L. Gilbert, Jon E. Stek, Giuseppe Villa, Stephanie O. Klopfer, Jason C. Martin, Florian Schödel, Prakash K. Bhuyan> ;Vaccine. 2014 Nov 12
6 citations
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates.
Gianmaria Minervini, Barbara J. McCarson, Keith S. Reisinger, Jason C. Martin, Jon E. Stek, Barbara Atkins, Karin B. Nadig, Vladimir Liska, Florian Schödel, Prakash K....> ;Vaccine. 2012 Feb 14
19 citations
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years
Christopher L. Gilbert, Stephanie O. Klopfer, Jason C. Martin, Florian Schödel, Prakash K. Bhuyan> ;Human Vaccines. 2011 Dec 1
3 citations
Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococ...
Andrew W. Lee, Timo Vesikari, Christopher L. Gilbert, Stephanie O. Klopfer, Florian Schödel, Prakash K. Bhuyan> ;Vaccine. 2011 Oct 19
7 citations
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants.
Timo Vesikari, Jason C. Martin, Charles Liss, Vladimir Liska, Florian Schödel, Prakash K. Bhuyan> ;The Pediatric Infectious Disease Journal. 2011 Jul 1
9 citations
Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b...
Francisco Diaz-Mitoma, Scott A. Halperin, Bruce Tapiero, Agnes Hoffenbach, Pamela S. Zappacosta, David Radley, Susan K. Bradshaw, Jason C. Martin, John W. Boslego, Ter...> ;Vaccine. 2011 Feb 1
3 citations
A randomized, multicenter, open-label clinical trial to assess the anamnestic immune response 4 to 8 years after a primary hepatitis B vaccination series.
Javier Díez-Domingo, Sheryl A. Flores, Jason C. Martin, Stephanie O. Klopfer, Florian Schödel, Prakash K. Bhuyan> ;The Pediatric Infectious Disease Journal. 2010 Oct 1
15 citations
Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3,...
Scott A. Halperin, Bruce Tapiero, Francisco Diaz-Mitoma, Barbara J. Law, Agnes Hoffenbach, Pamela S. Zappacosta, David Radley, Barbara J. McCarson, Jason C. Martin, La...> ;Vaccine. 2009 Apr 28
23 citations
Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults
Pierre Van Damme, Gianmaria Minervini, Charles Liss, Barbara J. McCarson, Timo Vesikari, John W. Boslego, Prakash K. Bhuyan> ;Human Vaccines. 2009 Feb 1
44 citations
Short Interfering RNA-Mediated Inhibition of Herpes Simplex Virus Type 1 Gene Expression and Function during Infection of Human Keratinocytes
Prakash Bhuyan, Katalin Karikó, John Capodici, John M. Lubinski, Lauren M. Hook, Harvey M. Friedman, Drew Weissman> ;Journal of Virology. 2004 Oct 1
330 citations
Small Interfering RNAs Mediate Sequence-Independent Gene Suppression and Induce Immune Activation by Signaling through Toll-Like Receptor 3
Katalin Karikó, Prakash Bhuyan, John Capodici, Drew Weissman> ;Journal of Immunology. 2004 Jun 1
64 citations
Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3.
Katalin Karikó, Prakash Bhuyan, John Capodici, Houping Ni, John M. Lubinski, Harvey M. Friedman, Drew Weissman> ;Cells, Tissues, Organs. 2004 Jan 1
36 citations
IDENTIFICATION OF THE RAT MATERNALLY TRANSMITTED MINOR HISTOCOMPATIBILITY ANTIGEN
Prakash K. Bhuyan, Lesley L. Young, Kirsten Fischer Lindahl, Geoffrey W. Butcher> ;Journal of Immunology. 1997 Apr 15
Join now to see all

Press Mentions

INOVIO to Present at Upcoming Investor Conferences in MarchMarch 2nd, 2021
Inovio Pharmaceuticals Inc (NASDAQ: INO) Q1 2020 Earnings Call TranscriptMay 11th, 2020
INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-Associated Vulvar DysplasiaMarch 30th, 2020
Join now to see all